Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Jucker

Showing results (201-210 of 208) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 208 results.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Aging Cell|June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's diseaseStephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Neuron|January 7, 2022
Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's diseaseFrederic Brosseron, Anne Maass, Luca Kleineidam, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Pageof 21

Showing results (201-210 of 208) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Aging Cell|June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's diseaseStephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Neuron|January 7, 2022
Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's diseaseFrederic Brosseron, Anne Maass, Luca Kleineidam, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Pageof 21